Communication of the meeting of Transparency Council No. 40/2025 on 15 September 2025 with resolutions
We invite you to read minutes of the meeting of Transparency Council No. 40/2025 on 15 September 2025 during which the following resolutions were adopted:
- At its meeting on 15 Septemeber 2025, the Transparency Council adopted position No. 119/2025 on the evaluation of Imfinzi (durvalumab) under drug program B.5. “Treatment of patients with hepatocellular carcinoma or bile duct cancer.”
- At its meeting on 15 Septemeber 2025, the Transparency Council adopted position No. 120/2025 on the evaluation of Imjudo (tremelimumab) under drug program B.5. “Treatment of patients with hepatocellular carcinoma or bile duct cancer.”
- At its meeting on 15 Septemeber 2025, the Transparency Council adopted position No. 121/2025 on the legitimacy of classifying the healthcare service “X-ray diagnostics – pantomographic image with description once every 3 years” as a guaranteed service.
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 166/2025 on the assessment of the validity of changing the reimbursement category of the active substance aflibercept.
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 167/2025 on the draft program “Prevention of hearing loss among secondary school students in the Zawiercie County for the years 2026-2028.”
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 168/2025 on the reimbursement of medicines containing the active substance octreotide for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics.
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 169/2025 on the reimbursement of medicines containing the active substance anastrozole for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics, i.e., hormone-dependent and HER2-negative breast cancer.
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 170/2025 on the reimbursement of medicines containing the active substance exemestane for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics, i.e., hormone-dependent and HER2-negative breast cancer.
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 171/2025 on the reimbursement of medicines containing the active substance letrozolum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics, i.e., hormone-dependent and HER2-negative breast cancer.
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 172/2025 on the reimbursement of medicines containing the active substance enoxaparinum natricum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics.
- At its meeting on 15 September 2025, the Transparency Council adopted opinion No. 173/2025 on the reimbursement of medicines containing the active substance nadroparinum calcicum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics.